On Jan. 22, 2021, Aurinia Pharmaceuticals announced that the FDA had approved LUPKYNISTM (voclosporin) in combination with a background immunosuppressive therapy regimen to treat adult patients with active lupus nephritis (LN).

LUPKYNIS is the first FDA-approved oral therapy for LN which causes irreversible kidney damage and significantly increases the risk of kidney failure, cardiac events, and death.